Tuesday, July 14

    Registration Open and Networking Breakfast

    WELCOME AND OPENING REMARKS

    Setting the Stage for the Day with an Overview of the Most Important Trends, Breakthroughs, and Opportunities Shaping the Future of Retinal Innovation

    Firas M. Rahhal, MD, Partner, Retina Vitreous Associates Medical Group; General Partner, ExSight Ventures, LLC , Partner , Retina Vitreous Associates Medical Grp

    8:35 - 9:35 AM: INNOVATION SHOWCASE 1

    Ashvattha Therapeutics | Susan Schneider, MD - Acting Chief Medical Officer

    Amaros | Ben Toker - Co-Founder & President

    Ocugenix | Sean McDonald - President & CEO

    Bioxytech Retina | Ali Basiri - CEO

    Alkeus Pharmaceuticals | Carlos Quezada Ruiz, MD - Chief Medical Officer

    Novaliq | Christian Roesky, PhD - CEO

    Retinal Protection Sciences | Matt Lessard - Chief Commercial Officer

    Stuart Therapeutics | Eric Schlumpf - President & CEO

    Oculis | Riad Sherif, MD - CEO

    THE RETINA STARTUP LIFECYCLE: From Discovery to Exit

    Panel Moderator:

    PANEL DISCUSSION:
    Leaders across the Innovation Ecosystem Discuss How Retinal Technologies Move from Early Discovery through Clinical Development, Financing, Partnerships, and Successful Exits

    John Pollack, MD, Partner, EyeSci Angels; Partner, Illinois Retina Associates , Partner , EyeSci Angels

    Networking Coffee Break

    10:55 - 11:45 AM: DURABLE THERAPIES IN RETINA SPOTLIGHT: EXTENDING TREATMENT BEYOND MONTHLY INJECTIONS

    Valitor | Greg Kunst - Chief Executive Officer

    Optigo Biosciences | Houman Hemmati, MD - Co-Founder & Chief Medical Officer

    REGENXBIO | Ram Palanki, PharmD - Chief Commercial Officer

    Re-Vana Therapeutics | Michael O’Rourke - Chief Executive Officer

    Uneedle | Sven Mentink - Director Ophthalmology

    EyePoint Pharmaceuticals

    Ocular Therapeutix | Peter K. Kaiser, MD - Chief Development Officer

    THE END OF MONTHLY VEG-F: HYPE OR REALITY?

    Panel Moderator:

    PANEL DISCUSSION:

    Baruch D Kuppermann, MD, PhD, Professor & Chair, Ophthalmology, University of California Irvine , Prof & Chair , Ophthalmology , Univ of California Irvine

    Panelists:

    Emmett T Cunningham, Jr. MD, PhD, MPH, Executive Chairman, Eyeconis / Senior Advisor, HealthQuest Captial Mgmt , Sr Advisor , Eyeconis HealthQuest Captial Mgmt , HealthQuest Capital

    Dilsher S Dhoot, MD, Vitreoretinal Surgeon, California Retina Consultants , Vitreoretinal Surgeon , California Retina Consultants

    THE GA DECISION POINT: TREAT EARLIER OR WAIT?

    Panel Moderator:

    PANEL DISCUSSION:

    Andrew A Moshfeghi, MD, MBA, Associate Professor, Clinical Ophthalmology, University of Southern California , Vice Chair , Clinical Ophthalmology , Univ of Southern California Roski Eye Institute

    Panelists:

    Michael A Singer, Clinical Professor, Ophthalmology, University of Texas San Antonio , Clinical Prof , Ophthalmology , Univ of Texas San Antonio

    Nadia K Waheed, Professor, Ophthalmology, New England Eye Center , Prof , Ophthalmology , New England Eye Ctr

    AI, IMAGING, AND PRECISION INTERVENTION: THE DIGITAL TRANSFORMATION OF RETINA

    Networking Luncheon

    1:40 - 2:10 PM: REGENERATIVE APPROACHES IN RETINAL DISEASE: FROM GENETIC REPAIR TO FUNCTIONAL RESTORATION

    Opus Genetics | George Magrath, MD, MBA - CEO

    Ray Therapeutics | Peter Francis, MD, PhD – Chief Medical and Scientific Officer

    Ocugen

    4DMT | Dhaval Desai, PharmD - Chief Development Officer

    CAPITAL IN RETINA: WHAT GETS FUNDED, WHAT DOESN’T AND WHY

    Panel Moderator:

    PANEL DISCUSSION:

    Paul Bresge, Co-Founder & CEO, Ray Therapeutics Inc. , Co Founder & CEO , Ray Therapeutics Inc

    THE IMPACT OF RECENT FDA GUIDANCE ON DRUG DEVELOPMENT

    Panel Moderator:

    PANEL DISCUSSION:

    Pravin U. Dugel, MD, Executive Chairman, President, and CEO, Ocular Therapeutix, Inc. , Executive Chairman, President, and CEO , Ocular Therapeutix, Inc.

    Panelists:

    Rael Mazansky, Managing Director, Deep Track Capital , Managing Director , Deep Track Capital

    Snehal Shah, PharmD, President, Research & Development, Oculis , President , R&D , Oculis

    Kuldev Singh, MD, MPH, Professor, Ophthalmology, Stanford University , Prof , Ophthalmology , Stanford Univ

    Networking Refreshment Break

    3:40 - 4:40 PM: INNOVATION SHOWCASE 2

    Synakis | Molly Shoichet - Co-Founder & Chief Scientific Officer

    Oxidium Therapeutics | Shelley Boyd - Founder & CEO / Chief Medical Officer

    OD-OS / Macutherm | Jan Tode, PhD - CMO, MacuTherm & Deputy Head, Hannover Medical School

    Ophthorobotics AG | Bernhard Günther - CEO & Chairman of the Board

    Adverum Biotechnologies- a wholly owned subsidiary of Eli Lilly and Company | Dina Akasheh - VP, Medical Affairs

    Surrozen | Daniel Chao, MD - Vice President, Head of Clinical Development

    Retinex | Andreas Gonzalez - Founder & Surgical Retina Specialist

    NeuroRays | Anita Trajkovska-Broach, PhD - Chief Scientific Officer

    RetinAI | Natasa Jovic - Vice President, Marketing Strategy & Research Partnerships

    Complement Therapeutics | Muhammad Ali Memon, MD - Chief Medical Officer

    VIEW FROM ASRS

    Panel Moderator:

    PANEL DISCUSSION:
    Leadership from the American Society of Retina Specialists Shares Frontline Perspectives on Emerging Clinical Trends, Innovation Adoption, and the Evolving Needs of Retina Physicians

    Gaurav K. Shah, MD, Retina Surgeon, West Coast Retina Medical Group; Chair, California Pacific Medical Center , Retina Surgeon , West Coast Retina Medical Group

    REVERSE PITCH

    Panel Moderator:

    PANEL DISCUSSION:
    Business Development Leaders Present Strategic Priorities and Partnership Needs, Offering Innovators Insight into What Major Companies Are Actively Seeking

    Firas M. Rahhal, MD, Partner, Retina Vitreous Associates Medical Group; General Partner, ExSight Ventures, LLC , Partner , Retina Vitreous Associates Medical Grp

    Networking Reception

    Close of Summit